Business Context and Reporting Period
Company: Advanced Micro Devices, Inc. (AMD)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2008
Event: Entry into a Material Definitive Agreement to form a manufacturing joint venture.
On October 6, 2008, AMD entered into a Master Transaction Agreement with Advanced Technology Investment Company LLC ("Oyster"), wholly owned by the Government of the Emirate of Abu Dhabi, and West Coast Hitech L.P. ("Pearl"). The agreement establishes "The Foundry Company," a Cayman Islands exempted company, to manufacture semiconductor products and provide foundry services.
Key Financial Metrics and Transaction Structure
This filing details a strategic restructuring rather than standard periodic financial results. Key financial terms include:
- Oyster Cash Contribution: Approximately $1.4 billion in cash to The Foundry Company.
- Cash to AMD: Oyster will transfer $0.7 billion in cash to AMD in exchange for 700,000 Class B Preferred Shares of The Foundry Company.
- Debt Assumption: The Foundry Company will assume approximately $1.2 billion of AMD's debt.
- Pearl Investment: AMD will issue 58 million shares of common stock and warrants to purchase 30 million shares (at $0.01 exercise price) to Pearl for an aggregate purchase price of approximately $314 million.
- Future Funding Commitment: Oyster is committed to providing additional equity funding of a minimum of $3.6 billion and up to $6.0 billion over the next five years.
- Ownership Structure: Immediately following closing, AMD will own 44.4% and Oyster 55.6% of The Foundry Company on a fully converted to common basis. Both parties will have equal voting rights.
Material Changes and Operational Impact
The transaction represents a material change in AMD's capital structure and manufacturing strategy:
- Asset Transfer: AMD will contribute Fab 30/38 and Fab 36 (German subsidiaries), manufacturing assets, real property, employees, inventories, and a portion of its patent portfolio to The Foundry Company.
- Supply Chain Restructuring: Under the Wafer Supply Agreement, AMD will purchase all of its microprocessor unit (MPU) requirements from The Foundry Company. GPU requirements will be purchased from The Foundry Company once a 32nm-qualified process is established.
- Executive Compensation: AMD CEO Dr. Hector de J. Ruiz will serve as non-voting Chairman of The Foundry Company Board. He will receive a base salary of $1,150,000 per year, a target annual bonus of 200% of base (up to 400%), and a transaction bonus of $3,000,000 upon closing.
Guidance, Risks, and Contingencies
Closing Conditions: The transaction is subject to several conditions, including:
- Receipt of government approvals, including HSR antitrust approval and merger control clearances.
- CFIUS (Committee on Foreign Investment in the United States) clearance regarding national security concerns.
- Approval by AMD stockholders for the issuance of shares and warrants.
- Continuation of economic incentives and subsidies from New York State for the proposed fab project in Saratoga County.
- Appointment of a Pearl nominee to AMD's board of directors.
Termination Rights: The agreement may be terminated by Oyster or Pearl if a material adverse effect occurs, if closing does not occur by March 7, 2009, or if CFIUS refers the transaction to the President of the United States.
Indemnification: AMD's liability for breaches of representations or warranties is capped at $700 million, with a $21 million threshold for aggregate indemnifiable damages.
Investor Verification Checklist
- Verify the status of CFIUS review and U.S. national security clearance.
- Confirm receipt of New York State economic incentives and subsidies for the Saratoga County fab project.
- Monitor the timeline for the public ground-breaking of Fab 4X in New York, which triggers warrant exercisability.
- Review the specific terms of the $1.2 billion debt assumption and its impact on AMD's remaining balance sheet.
- Assess the implications of the 55.6% economic ownership by Oyster and the potential for future dilution or capital infusion requirements.